Literature DB >> 9574657

Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report.

A L Barkan1, W F Chandler.   

Abstract

OBJECTIVE AND IMPORTANCE: We present a case of a giant prolactinoma with a falsely low serum prolactin concentration determined by a two-site chemiluminometric assay. Awareness of the possibility of the "high-dose hook effect" in such cases will prevent preoperative misdiagnosis. CLINICAL
PRESENTATION: A patient with a giant invasive pituitary tumor was found preoperatively to have serum prolactin of 31 ng/ml. Pathological examination of the excised tissue, however, demonstrated strong staining for prolactin. INTERVENTION: Serial dilutions of the serum disclosed hyperprolactinemia of 280,000 ng/ml, establishing the presence of the "high-dose hook effect." Treatment with pergolide (Permax; Athena Neurosciences, S. San Francisco, CA) decreased tumor size and lowered serum prolactin by more than 99%.
CONCLUSION: A "high-dose hook effect" needs to be suspected in every patient with a giant pituitary adenoma (>3 cm) and normal serum prolactin. Subsequently assaying the diluted serum will reliably disclose this phenomenon and allow correct diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574657     DOI: 10.1097/00006123-199804000-00126

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  15 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 2.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 3.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

Review 4.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

Review 5.  A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.

Authors:  J Berwaerts; J Verhelst; R Abs; B Appel; C Mahler
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

6.  Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.

Authors:  Felice Esposito; Daniel F Kelly; Harry V Vinters; Antonio A F DeSalles; Joel Sercarz; Alessandra A Gorgulhos
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

7.  Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'.

Authors:  Maria Fleseriu; Michael Lee; Maria M Pineyro; Mario Skugor; Sethu K Reddy; Elias S Siraj; Amir H Hamrahian
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

8.  Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.

Authors:  Susana Mascarell; David H Sarne
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

9.  Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Authors:  Yinxing Huang; Chenyu Ding; Fangfang Zhang; Deyong Xiao; Lin Zhao; Shousen Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

10.  Falsely low serum prolactin in two cases of invasive macroprolactinoma.

Authors:  Christof Schöfl; Beate Schöfl-Siegert; Johann Hinrich Karstens; Michael Bremer; Thomas Lenarz; Jose Sebastian Fernandez Cuarezma; Madjid Samii; Alexander von zur Mühlen; Georg Brabant
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.